Although at present there are no indications of recurrent KDM4B mutations in BCa, or indeed other cancer types, acquisition of activating mutations in KDM4B or KDM4B gene silencing by methylation may be a contributory factor in the persistence or loss of ER expression during BCa development and response to treatment. This evidence concerns the gene KDM4B and cancer.